4.05
price down icon2.64%   -0.11
after-market アフターアワーズ: 4.03 -0.02 -0.49%
loading

Replimune Group Inc (REPL) 最新ニュース

pulisher
Sep 24, 2025

Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot

Sep 24, 2025
pulisher
Sep 24, 2025

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView

Sep 24, 2025
pulisher
Sep 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire

Sep 23, 2025
pulisher
Sep 22, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Sep 22, 2025
pulisher
Sep 22, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent

Sep 22, 2025
pulisher
Sep 22, 2025

Strategies to average down on Replimune Group Inc.Market Movers & Technical Buy Zone Confirmation - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - Morningstar

Sep 22, 2025
pulisher
Sep 22, 2025

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Sep 22, 2025
pulisher
Sep 22, 2025

Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News

Sep 22, 2025
pulisher
Sep 22, 2025

Tools to assess Replimune Group Inc.’s risk profilePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse

Sep 22, 2025
pulisher
Sep 22, 2025

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

Join Class Action to Recover Losses from Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - Barchart.com

Sep 22, 2025
pulisher
Sep 21, 2025

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Sep 21, 2025
pulisher
Sep 21, 2025

REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire

Sep 21, 2025
pulisher
Sep 21, 2025

REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - GlobeNewswire Inc.

Sep 21, 2025
pulisher
Sep 21, 2025

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - Stockhouse

Sep 21, 2025
pulisher
Sep 21, 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire

Sep 21, 2025
pulisher
Sep 21, 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire Inc.

Sep 21, 2025
pulisher
Sep 21, 2025

REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

Sep 21, 2025
pulisher
Sep 20, 2025

2025-09-20 | REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. InvestorsLead Plaintiff Deadline September 22, 2025 | NDAQ:REPL | Press Release - Stockhouse

Sep 20, 2025
pulisher
Sep 20, 2025

REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL | FinancialContent - FinancialContent

Sep 20, 2025
pulisher
Sep 20, 2025

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action PendingHagens Berman - PR Newswire

Sep 20, 2025
pulisher
Sep 20, 2025

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha

Sep 20, 2025
pulisher
Sep 20, 2025

JPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL) - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile

Sep 20, 2025
pulisher
Sep 20, 2025

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire

Sep 20, 2025
pulisher
Sep 19, 2025

Analyzing recovery setups for Replimune Group Inc. investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph

Sep 19, 2025
pulisher
Sep 19, 2025

Why Replimune Stock Was Tumbling Again Today - AOL.com

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgrade - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Insider Monkey

Sep 19, 2025
pulisher
Sep 19, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Sep 19, 2025
pulisher
Sep 19, 2025

JP Morgan Downgrades Replimune Group (REPL) to Underweight | REP - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune stock unchanged as H.C. Wainwright maintains Neutral rating - Investing.com

Sep 19, 2025
pulisher
Sep 19, 2025

This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga

Sep 19, 2025
pulisher
Sep 19, 2025

BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire

Sep 19, 2025
pulisher
Sep 19, 2025

Factset, Metlife, Replimune - TradingView

Sep 19, 2025
pulisher
Sep 19, 2025

Replimune stock rating downgraded by JPMorgan on regulatory concerns - Investing.com

Sep 19, 2025
pulisher
Sep 19, 2025

Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL - MarketBeat

Sep 19, 2025
pulisher
Sep 18, 2025

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

Sep 18, 2025
pulisher
Sep 18, 2025

Why Replimune Stock Plummeted by Almost 40% Today - MSN

Sep 18, 2025
pulisher
Sep 18, 2025

Replimune (REPL) Faces Setback After FDA Meeting - GuruFocus

Sep 18, 2025
pulisher
Sep 18, 2025

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire

Sep 18, 2025
pulisher
Sep 18, 2025

REPLIMUNE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the FirmREPL - MarketScreener

Sep 18, 2025
pulisher
Sep 18, 2025

Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire

Sep 18, 2025
pulisher
Sep 18, 2025

Shareholders that lost money on Replimune Group, Inc. - GlobeNewswire

Sep 18, 2025
pulisher
Sep 18, 2025

Replimune stock plunges after FDA meeting fails to clear path forward - Investing.com Australia

Sep 18, 2025
pulisher
Sep 18, 2025

Replimune Group Completes FDA Meeting on RP1 Application - TipRanks

Sep 18, 2025
pulisher
Sep 18, 2025

Replimune Stock Plunged 42% Today – Here’s Why - Stocktwits

Sep 18, 2025
pulisher
Sep 18, 2025

Melanoma drug developer stock crashes after report from FDA meeting - The Business Journals

Sep 18, 2025
$34.90
price down icon 2.43%
$81.66
price down icon 2.97%
$28.84
price down icon 2.07%
$98.08
price down icon 1.67%
$135.59
price down icon 3.84%
biotechnology ONC
$328.71
price down icon 0.34%
大文字化:     |  ボリューム (24 時間):